Research Study

An Open-Label, Non-Randomized Registry of the Natural Use of Paliperidone Palmitate in Canada: Canadian Sustenna Treatment Assessment Registry (CANSTAR)
Principal Investigator 
Soma Ganesan

Overview

Body Locations and Systems 
Brain and Nerves
Disorders and Conditions 
Schizophrenia
Study Start/End 
Sep 1, 2015 to Dec 31, 2015
Locations 
Vancouver General Hospital
Name/Title 
Boris Feldman
Phone 
604-875-5823
Email Address 
boris.feldman@vch.ca
Purpose of Study 

The purpose of this study is to collect data on patients in Canada who are switching from oral antipsychotic therapy to INVEGA® SUSTENNA® to treat schizophrenia.

The goals of the study are:

To look at how treatment with INVEGA SUSTENNA affects patients with schizophrenia.
To understand how long-acting treatments are being used in everyday clinical practice.

Eligibility 

19 to 65 years of age
Diagnosed with Schizophrenia
Able and willing to comply with the study protocol
Ambulatory (not chronically hospitalized)
Switching from an oral antipsychotic medication to INVEGA SUSTENNA
Competent to give informed consent

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.